title: [Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy].
authors.forename: Lionel
authors.initials: L
authors.lastname: Apetoh
authors.forename: François
authors.initials: F
authors.lastname: Ghiringhelli
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
mesh_terms: D000818:Animals; D000943:Antigens, Differentiation; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D037282:Calreticulin / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology* / Q000627:therapeutic use; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D016923:Cell Death / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D005786:Gene Expression Regulation / Q000187:drug effects; D007107:Immune System / Q000187:drug effects* / Q000528:radiation effects*; D007371:Interferon-gamma / Q000502:physiology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000528:radiation effects; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy; D010587:Phagocytosis; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors; D054645:Protein Phosphatase 1; D051381:Rats; D011994:Recombinant Proteins / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology
chemical_list: D000943:Antigens, Differentiation; D000970:Antineoplastic Agents; D037282:Calreticulin; D018797:Cell Cycle Proteins; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D007371:Interferon-gamma; C087519:PPP1R15A protein, human; D010749:Phosphoprotein Phosphatases; C513256:Ppp1r15a protein, mouse; D054645:Protein Phosphatase 1